文献速递肝病

关于代谢相关脂肪性肝病与非酒精性脂肪性肝病在患病率和危险因素差异上的观察性数据Meta分析

An Observational Data Meta-analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD.
PubMed 文献 · Clin Gastroenterol Hepatol · 2021-12-04

该Meta分析纳入22篇文献共379,801例患者,比较代谢相关脂肪性肝病(MAFLD)与非酒精性脂肪性肝病(NAFLD)的患病率及危险因素差异。MAFLD合并患病率为39.22%(95%CI 30.96%-48.15%),现行MAFLD定义仅覆盖81.59%(95%CI 66.51%-90.82%)的NAFLD诊断。MAFLD诊断与男性、较高体质指数、高血压、糖尿病、血脂异常、转氨酶升高及更高纤维化评分相关。

要点

  • MAFLD合并患病率39.22%(95%CI 30.96%-48.15%),欧洲和亚洲最高,其次为北美。
  • 现行MAFLD定义仅覆盖81.59%(95%CI 66.51%-90.82%)的NAFLD诊断。
  • MAFLD与男性、较高体质指数、高血压、糖尿病、血脂异常、转氨酶升高及更高纤维化评分显著相关。

核心结论

  • MAFLD与NAFLD在患病率和危险因素方面存在显著差异。
  • 应用MAFLD定义时,需更重视合并代谢疾病的管理并协作探索疾病复杂的病理生理机制。

研究设计与样本

  • 观察性数据Meta分析,检索Medline和Embase数据库,纳入关于MAFLD或NAFLD患病率、危险因素或结局的文章。
  • 共纳入22篇文章,涉及379,801例患者;采用广义线性混合模型进行比例Meta分析,危险因素和结局采用传统配对Meta分析。

主要发现

  • MAFLD合并患病率为39.22%(95%CI 30.96%-48.15%),欧洲和亚洲患病率最高,其次为北美。
  • 现行MAFLD定义仅覆盖81.59%(95%CI 66.51%-90.82%)的NAFLD诊断。
  • 与NAFLD相比,患者被诊断为MAFLD的比值比为1.37(95%CI 1.16-1.63;P < .001)。
  • 影像学检查方式下诊断为MAFLD的比值显著高于NAFLD,但活检方式下无此差异。
  • 与NAFLD相比,MAFLD与男性、较高体质指数、高血压、糖尿病、血脂异常、转氨酶升高及更高纤维化评分显著相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The shift to redefine nonalcoholic fatty liver disease (NAFLD) as metabolic associated fatty liver disease (MAFLD) can profoundly affect patient care, health care professionals, and progress within the field. To date, there remains no consensus on the characterization of NAFLD vs MAFLD. Thus, this study sought to compare the differences between the natural history of NAFLD and MAFLD. METHODS: Medline and Embase databases were searched to include articles on prevalence, risk factors, or outcomes of patients with MAFLD or NAFLD. Meta-analysis of proportions was conducted using the generalized linear mix model. Risk factors and outcomes were evaluated in conventional pairwise meta-analysis. RESULTS: Twenty-two articles involving 379,801 patients were included. Pooled prevalence of MAFLD was 39.22% (95% confidence interval [CI], 30.96%-48.15%) with the highest prevalence in Europe and Asia, followed by North America. The current MAFLD Definition only accounted for 81.59% (95% CI, 66.51%-90.82%) of NAFLD diagnoses. Patients had increased odds of being diagnosed with MAFLD compared with NAFLD (odds ratio, 1.37; 95% CI, 1.16-1.63; P < .001). Imaging modality resulted in a significantly higher odds of being diagnosed with MAFLD compared with NAFLD, but not biopsy. MAFLD was significantly associated with males, higher body mass index, hypertension, diabetes, lipids, transaminitis, and greater fibrosis scores compared with NAFLD. CONCLUSIONS: There were stark differences in the prevalence and risk factors between MAFLD and NAFLD. However, in the use of the MAFLD Definition, a greater emphasis on the management of concomitant metabolic diseases and a collaborative effort is required to explore the complex pathophysiologic mechanisms underlying the disease.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Lim GEH, Tang A, Ng CH, et al. An Observational Data Meta-analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD. Clin Gastroenterol Hepatol. 2021. PMID: 34871813. doi:10.1016/j.cgh.2021.11.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。